Collectively, COL5A2 facilitates malignant phenotypes of GC through inducing EMT via promoting the protein expressions of SNAI1, SNAI2, TWIST, VIM, and MMP2, demonstrating the oncogenic role of COL5A2 in GC and providing a novel clue for the therapeutic application of COL5A2 in GC. This evidence concerns the gene SNAI2 and gastric cancer.